Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2021 pubmed 13 citations

Sequence determinants in the cathelicidin LL-37 that promote inflammation via presentation of RNA to scavenger receptors.

Kulkarni. Nikhil N NN; O'Neill. Alan M AM; Dokoshi. Tatsuya T; Luo. Elizabeth W C EWC; Wong. Gerard C L GCL; Gallo. Richard L RL

Key Findings

  • Alanine changes on the hydrophobic face of LL‑37 block its ability to promote type‑I interferon by preventing RNA presentation to scavenger receptor‑B1.
  • These same changes do not reduce, and can even increase, the peptide’s antimicrobial activity against bacteria like Staph aureus and group A Strep.
  • LL‑37 can still organize RNA into structures that activate TLR‑3, but without scavenger‑receptor binding the overall inflammatory response is lost.

Practical Outcomes

  • For DIY health enthusiasts, this suggests that raw LL‑37 supplements might trigger unwanted inflammation by interacting with RNA. Modifying the peptide’s oily region could retain antimicrobial benefits while lowering inflammatory risk, pointing to safer peptide designs for future self‑experiments.

Summary

Scientists studied the human peptide LL‑37 and found that changing certain building blocks on its oily side stops it from causing inflammation by handing over RNA to cell surface receptors, while still keeping its ability to kill microbes. This means the inflammatory effect of LL‑37 can be separated from its antimicrobial action.

Abstract

Cathelicidins such as the human 37-amino acid peptide (LL-37) are peptides that not only potently kill microbes but also trigger inflammation by enabling immune recognition of endogenous nucleic acids. Here, a detailed structure-function analysis of LL-37 was performed to understand the details of this process. Alanine scanning of 34-amino acid peptide (LL-34) showed that some variants displayed increased antimicrobial activity against Staphylococcus aureus and group A Streptococcus. In contrast, different substitutions clustered on the hydrophobic face of the LL-34 alpha helix inhibited the ability of those variants to promote type 1 interferon expression in response to U1 RNA or to present U1 to the scavenger receptor (SR) B1 on the keratinocyte cell surface. Small-angle X-ray scattering experiments of the LL-34 variants LL-34, F5A, I24A, and L31A demonstrated that these peptides form cognate supramolecular structures with U1 characterized by inter-dsRNA spacings of approximately 3.5 nm, a range that has been previously shown to activate toll-like receptor 3 by the parent peptide LL-37. Therefore, while alanine substitutions on the hydrophobic face of LL-34 led to loss of binding to SRs and the complete loss of autoinflammatory responses in epithelial and endothelial cells, they did not inhibit the ability to organize with U1 RNA in solution to associate with toll-like receptor 3. These observations advance our understanding of how cathelicidin mediates the process of innate immune self-recognition to enable inert nucleic acids to trigger inflammation. We introduce the term "innate immune vetting" to describe the capacity of peptides such as LL-37 to enable certain nucleic acids to become an inflammatory stimulus through SR binding prior to cell internalization.

Study Information

Provider

pubmed

Year

2021

Date

2021-05-26T00:00:00.000Z

DOI

10.1016/j.jbc.2021.100828

Citations

13

References

50